Alterity Therapeutics Halts Trading Ahead of Critical Phase II Neurodegenerative Disease Trial Results
Alterity Therapeutics has implemented a trading halt on its securities pending the announcement of results from a crucial Phase II clinical trial. The halt will remain in effect until the results are disclosed or until trading resumes on January 30, 2025, marking a significant moment for the biotechnology company's neurodegenerative disease program.
Alterity Therapeutics' ATH434 Shows Promise in Multiple System Atrophy Trials
• Alterity Therapeutics anticipates topline data from the ATH434-201 Phase 2 trial in early-stage Multiple System Atrophy (MSA) by early February 2025.
• Interim data from the ATH434-202 Phase 2 trial in advanced MSA suggests potential disease-modifying effects, with 30% of participants showing stable or improved clinical outcomes.
• Non-clinical data highlights ATH434's neuroprotective qualities and mechanism of action, emphasizing the importance of iron-targeting agents in treating neurodegenerative diseases.
• The bioMUSE natural history study demonstrates the utility of advanced neuroimaging to track MSA progression, correlating brain volume reductions with clinical worsening.
Opthea Reports Positive Phase 1b DME Trial Results
Opthea Limited has announced positive results from its Phase 1b trial of sozinibercept for diabetic macular edema (DME), showing the treatment's safety and efficacy when combined with standard anti-VEGF-A therapy. The trial, involving nine patients, demonstrated significant improvements in visual acuity and reductions in central subfield thickness, indicating potential for a novel DME treatment approach.
Alterity's ATH434 Shows Promise in Phase 2 Trial for Multiple System Atrophy
• Alterity Therapeutics' ATH434 demonstrated a statistically significant 48% slowing of clinical progression in early-stage MSA patients at the 50 mg dose.
• MRI biomarkers indicated that ATH434 reduced iron accumulation in key brain regions affected by MSA, suggesting a potential disease-modifying effect.
• The Phase 2 trial showed a favorable safety profile for ATH434, with most adverse events being mild to moderate and no treatment-related serious adverse events reported.
• Alterity plans to engage with the FDA to discuss accelerating the development of ATH434, addressing the unmet need for MSA treatments.
© Copyright 2025. All Rights Reserved by MedPath